Clinical Trials Browser

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05489211 2025-07-11

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

582 enrolled

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Phase 2 Completed

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04720131 2024-01-30

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Phase 2 Completed

28 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03111732 2021-12-03

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Phase 2 Completed

11 enrolled 16 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT03231176 2020-11-19

Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

Phase 2 Completed

62 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT02350686 2019-05-20

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

Phase 2 Unknown

67 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03609489 2018-08-09

A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma

Phase 2 Unknown

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03129074 2018-05-23

Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT00142480 2018-04-25

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Phase 2 Completed

8 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02558959 2018-02-13

Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

Phase 2 Completed

64 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02720601 2018-01-25

Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT01572324 2017-01-04

Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas

Phase 2 Completed

37 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT00868998 2016-05-23

GTX Regimen for Biliary Cancers

Phase 2 Terminated

4 enrolled 7 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT01530503 2016-02-25

BIT-2

Phase 2 Completed

52 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT00338988 2012-08-01

Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

Phase 2 Completed

44 enrolled 5 charts

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms